$SVRA
Savara Inc

2017 Q1 Form 10-Q Financial Statement

#000156459017009915 Filed on May 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.740M $350.0K
YoY Change 397.14% -90.22%
% of Gross Profit
Research & Development $2.950M $1.260M
YoY Change 134.13% -79.14%
% of Gross Profit
Depreciation & Amortization $90.00K $30.00K
YoY Change 200.0% 0.0%
% of Gross Profit
Operating Expenses $5.791M $10.74M
YoY Change -46.09% 11.32%
Operating Profit -$4.774M -$1.691M
YoY Change 182.32% -82.48%
Interest Expense $178.0K $519.0K
YoY Change -65.7%
% of Operating Profit
Other Income/Expense, Net -$437.0K $15.00K
YoY Change -3013.33% 275.0%
Pretax Income -$5.211M -$1.680M
YoY Change 210.18% -82.54%
Income Tax -$237.0K
% Of Pretax Income
Net Earnings -$4.974M -$1.676M
YoY Change 196.78% -82.57%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.640M -$1.615M
COMMON SHARES
Basic Shares Outstanding 254.7M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.800M $37.10M
YoY Change -78.98% -25.65%
Cash & Equivalents $10.46M $23.52M
Short-Term Investments $0.00 $13.60M
Other Short-Term Assets $400.0K $1.200M
YoY Change -66.67% 71.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.200M $38.20M
YoY Change -78.53% -24.51%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $200.0K
YoY Change -50.0% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K
YoY Change 0.0% -75.0%
Total Long-Term Assets $5.700M $11.90M
YoY Change -52.1% -1.65%
TOTAL ASSETS
Total Short-Term Assets $8.200M $38.20M
Total Long-Term Assets $5.700M $11.90M
Total Assets $13.90M $50.10M
YoY Change -72.26% -20.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $500.0K $2.500M
YoY Change -80.0% 8.7%
Accrued Expenses $4.500M $8.800M
YoY Change -48.86% 27.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.600M $11.40M
YoY Change -85.96%
Total Short-Term Liabilities $6.600M $22.70M
YoY Change -70.93% 146.74%
LONG-TERM LIABILITIES
Long-Term Debt $1.900M $0.00
YoY Change
Other Long-Term Liabilities $3.400M
YoY Change
Total Long-Term Liabilities $1.900M $3.400M
YoY Change -44.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.600M $22.70M
Total Long-Term Liabilities $1.900M $3.400M
Total Liabilities $9.500M $29.47M
YoY Change -67.76% 133.63%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $321.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.400M $20.70M
YoY Change
Total Liabilities & Shareholders Equity $13.90M $50.10M
YoY Change -72.26% -20.12%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$4.974M -$1.676M
YoY Change 196.78% -82.57%
Depreciation, Depletion And Amortization $90.00K $30.00K
YoY Change 200.0% 0.0%
Cash From Operating Activities -$2.840M -$11.33M
YoY Change -74.93% 54.15%
INVESTING ACTIVITIES
Capital Expenditures $59.00K $5.000K
YoY Change 1080.0% -92.86%
Acquisitions
YoY Change
Other Investing Activities $0.00 $4.380M
YoY Change -100.0% -1073.33%
Cash From Investing Activities -$60.00K $4.380M
YoY Change -101.37% -942.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.060M
YoY Change 89455.56%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 7.420M
YoY Change -100.0% -74300.0%
NET CHANGE
Cash From Operating Activities -2.840M -11.33M
Cash From Investing Activities -60.00K 4.380M
Cash From Financing Activities 0.000 7.420M
Net Change In Cash -2.900M 470.0K
YoY Change -717.02% -105.96%
FREE CASH FLOW
Cash From Operating Activities -$2.840M -$11.33M
Capital Expenditures $59.00K $5.000K
Free Cash Flow -$2.899M -$11.34M
YoY Change -74.42% 52.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1580000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-311073000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
255000
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
321037000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000
CY2017Q1 svra In Process Research And Development
InProcessResearchAndDevelopment
2500000
CY2016Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
2500000
CY2016Q1 us-gaap Interest Expense
InterestExpense
519000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
9759000
CY2017Q1 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
1933000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17922000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3639241
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3639241
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
11000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
5791000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5697000
CY2017Q1 svra Transaction Related Expense Income Net
TransactionRelatedExpenseIncomeNet
2752000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
659000
CY2016Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
169000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-515000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-153000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
32000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
10742000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10742000
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
11000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
39000
CY2017Q1 us-gaap Interest Expense
InterestExpense
178000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
461000
CY2017Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
104000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-127000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-776000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1726000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-358000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3179000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11328000
CY2017Q1 svra Maturity Of Certificate Of Deposits
MaturityOfCertificateOfDeposits
498000
CY2016Q1 svra Maturity Of Certificate Of Deposits
MaturityOfCertificateOfDeposits
4383000
CY2017Q1 svra Proceeds From Sale Of Certificate Of Deposit
ProceedsFromSaleOfCertificateOfDeposit
2241000
CY2017Q1 svra Proceeds From Security Deposits
ProceedsFromSecurityDeposits
90000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2829000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4378000
CY2017Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
368000
CY2017Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
50000
CY2016Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
38000
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8060000
CY2016Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
601000
CY2017Q1 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
3000
CY2016Q1 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
2000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-421000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7419000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-771000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
469000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23052000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23521000
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in Mast&#8217;s consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and assumptions, including estimates related to R&amp;D expenses, in-process research and development (&#8220;IPR&amp;D&#8221;), goodwill, and share-based compensation expenses. We base our estimates on historical experience and various other relevant assumptions we believe to be reasonable under the circumstances. Actual results may differ from these estimates.</p></div>
CY2017Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
7800000
CY2017Q1 svra Working Capital
WorkingCapital
1600000
CY2017Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
5507000
CY2016Q4 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
2739000
CY2016 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1000
CY2017Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
0
CY2017Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
0
CY2017Q1 us-gaap Capital Lease Obligations
CapitalLeaseObligations
40000
CY2017Q1 svra Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1255000
CY2016Q4 svra Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1401000
CY2017Q1 svra Accrued Transaction Related Expenses
AccruedTransactionRelatedExpenses
733000
CY2016Q4 svra Accrued Transaction Related Expenses
AccruedTransactionRelatedExpenses
248000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
253000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
325000
CY2017Q1 us-gaap Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
The interest rate for the principal balance under the Loan Agreement is the greater of (i) 8.95% plus the prime rate as reported in The Wall Street Journal minus 3.25%, and (ii) 8.95%, determined on a daily basis.
CY2015 us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.0895
CY2015 us-gaap Debt Instrument Interest Rate Increase Decrease
DebtInstrumentInterestRateIncreaseDecrease
-0.0325
CY2017Q1 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.0970
CY2015Q4 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
712500
CY2017Q1 us-gaap Line Of Credit Facility Frequency Of Payment And Payment Terms
LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms
The interest rate for the principal balance under the Loan Agreement is the greater of (i) 8.95% plus the prime rate as reported in The Wall Street Journal minus 3.25%, and (ii) 8.95%, determined on a daily basis. The interest rate as of March 31, 2017 was 9.70%. Monthly payments under the Loan Agreement were interest only until July 1, 2016. On July 1, 2016, Mast started making monthly payments of principal and interest. Payments will continue through the scheduled maturity date of January 1, 2019.
CY2017Q1 svra Debt Prepayment Charge Rate On Principal Balance
DebtPrepaymentChargeRateOnPrincipalBalance
0.02
CY2017Q1 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
712500
CY2017Q1 svra Principal Payments Of Debt And End Of Term Charge Current
PrincipalPaymentsOfDebtAndEndOfTermChargeCurrent
1555000
CY2017Q1 us-gaap Interest Payable Current
InterestPayableCurrent
25000
CY2017Q1 svra Principal Payments Of Debt And End Of Term Charge Non Current
PrincipalPaymentsOfDebtAndEndOfTermChargeNonCurrent
2135000
CY2017Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
145000
CY2017Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
57000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
461000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
659000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
315203
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
29386
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
285817
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
46.38
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
72588
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
227
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
72361
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.80
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
9.80
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
9.80
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2100000
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2017Q1 svra Number Of Stock Options To Purchase Common Stock Terminate Before Merger If Not Exercised
NumberOfStockOptionsToPurchaseCommonStockTerminateBeforeMergerIfNotExercised
239801
CY2017Q1 us-gaap Interest Paid
InterestPaid
76000
CY2016Q1 us-gaap Interest Paid
InterestPaid
288000
CY2016Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
26000
CY2017Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1000
CY2016Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
22000
CY2016Q1 svra Finance Costs Included In Accounts Payable And Accrued Liabilities
FinanceCostsIncludedInAccountsPayableAndAccruedLiabilities
167000
CY2017Q1 svra Debt Issuance Costs Included In Accounts Payable And Accrued Liabilities
DebtIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
3000
CY2016Q1 svra Debt Issuance Costs Included In Accounts Payable And Accrued Liabilities
DebtIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
10000
CY2016Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
8000000
CY2016Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
415584
CY2016Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
415584
CY2016Q1 svra Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
7300000
CY2016Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
29.40
CY2016Q1 svra Class Of Warrant Or Rights Expiration Date
ClassOfWarrantOrRightsExpirationDate
2021-02-16
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1042905
svra Weighted Average Sales Price
WeightedAverageSalesPrice
28.00
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
29400000
svra Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
28100000
svra Proceeds From Remaining Issuance Or Sale Of Equity
ProceedsFromRemainingIssuanceOrSaleOfEquity
18000000
CY2017Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1152231

Files In Submission

Name View Source Status
0001564590-17-009915-index-headers.html Edgar Link pending
0001564590-17-009915-index.html Edgar Link pending
0001564590-17-009915.txt Edgar Link pending
0001564590-17-009915-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
svra-10q_20170331.htm Edgar Link pending
svra-20170331.xml Edgar Link completed
svra-20170331.xsd Edgar Link pending
svra-20170331_cal.xml Edgar Link unprocessable
svra-20170331_def.xml Edgar Link unprocessable
svra-20170331_lab.xml Edgar Link unprocessable
svra-20170331_pre.xml Edgar Link unprocessable
svra-ex1012_101.htm Edgar Link pending
svra-ex1013_99.htm Edgar Link pending
svra-ex1014_100.htm Edgar Link pending
svra-ex1015_98.htm Edgar Link pending
svra-ex1016_267.htm Edgar Link pending
svra-ex1017_97.htm Edgar Link pending
svra-ex103_269.htm Edgar Link pending
svra-ex311_6.htm Edgar Link pending
svra-ex312_8.htm Edgar Link pending
svra-ex321_7.htm Edgar Link pending
svra-ex42_270.htm Edgar Link pending
svra-ex43_268.htm Edgar Link pending